AF9 antibody (C-Term)

Catalog No. ABIN390128

The Rabbit Polyclonal anti-AF9 antibody has been validated for WB and IHC (p). It is suitable to detect AF9 in samples from Human. There are 2+ publications available.

Quick Overview for AF9 antibody (C-Term) (ABIN390128)

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This AF9 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB2249-2250

Product Details anti-AF9 Antibody

Binding Specificity: AA 471-502, C-Term

Predicted Reactivity: M

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-AF9 antibody (ABIN390128)

Benedikt, Baltruschat, Scholz, Bursen, Arrey, Meyer, Varagnolo, Müller, Karas, Dingermann, Marschalek: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." in: Leukemia, Vol. 25, Issue 1, pp. 135-44, (2011) (PubMed).

Bitoun, Oliver, Davies: "The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling." in: Human molecular genetics, Vol. 16, Issue 1, pp. 92-106, (2007) (PubMed).

Target Details for AF9

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Alternative Name: AF9 (MLLT3)

Background: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Molecular Weight: 63351

Gene ID: 4300

NCBI Accession: NP_004520

UniProt: P42568